- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 1344307 [Title] => Access program helps poor cancer patients get treatment [Summary] =>A patient support group has lauded Novartis Healthcare Philippines for its unprecedented access program that helps underprivileged patients get the cancer treatments they need.
[DatePublished] => 2014-07-10 00:00:00 [ColumnID] => 0 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => http://media.philstar.com/images/the-philippine-star/business/science-and-technology/20140710/Max-Philippines-Novartis-Healthcare.jpg ) [1] => Array ( [ArticleID] => 464588 [Title] => Reducing risk of cancer returning in patients [Summary] =>MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
[DatePublished] => 2009-05-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
NOVARTIS ONCOLOGY ACCESS
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 1344307 [Title] => Access program helps poor cancer patients get treatment [Summary] =>A patient support group has lauded Novartis Healthcare Philippines for its unprecedented access program that helps underprivileged patients get the cancer treatments they need.
[DatePublished] => 2014-07-10 00:00:00 [ColumnID] => 0 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => http://media.philstar.com/images/the-philippine-star/business/science-and-technology/20140710/Max-Philippines-Novartis-Healthcare.jpg ) [1] => Array ( [ArticleID] => 464588 [Title] => Reducing risk of cancer returning in patients [Summary] =>MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
[DatePublished] => 2009-05-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
EZ2 - 26 15
SUERTRES - 8 7 1
6D Lotto - 3 5 0 1 1 4
6/42 Lotto - 3 30 27 17 29 20
P9,591,316.00
6/49 Super Lotto - 40 12 37 24 27 18
P15,840,000.00
- 12:00 am